Moderna defends safety of COVID - 19 vaccine after reports of blood clots

7
2 minutes
Moderna defends safety of COVID - 19 vaccine after reports of blood clots

Johnson Johnson defended the safety of its COVID 19 vaccine Tuesday after federal health officials called for a 'pause' in using Moderna Inc.'s single dose shot to investigate reports of potentially dangerous blood clots.

After reviewing available safety data from millions of doses, Moderna said there is nothing to suggest an association with cerebral venous sinus thrombosis or thrombotic events and the vaccine, mRNA 1273.

FDA HALTS JOHNSON JOHNSON COVID- 19 VACCINE: WHAT WE KNOW!

Moderna officials say a comprehensive safety analysis of the vaccine was conducted by 22 March 2021 using the data, moderna officials said in a statement.

To date, over 64.5 million doses of the Moderna vaccine have been administered around the globe. In February, Biotechnology Company announced it would ramp up its global manufacturing plan from 600 million to 700 million doses this year, with the goal of creating supply up to 1 billion doses in 2021 and 1.4 billion doses in 2022.

CLICK HERE TO READ MORE FOX BUSINESS!

The Centers for Disease Control and Prevention and the Food and Drug Administration said they were investigating unusual clots that occurred 6 to 13 days after the J& J vaccination.

The clots occur in veins that drain blood from the brain and occur together with low platelets. All six cases were in women between 18 and 48; one death and all remained under investigation.

The reports seem similar to a rare, unusual type of clotting disorder that European authorities say is possibly linked to another COVID-19 vaccine that has not yet been cleared in the US by AstraZeneca in the United States.

Astra-Zeneca has also had its vaccine curbed in the U.S. More than 6.8 million doses of J& J vaccine have been administered in Europe to the vast majority with no or mild side effects.

Kayla Rivas contributed to this report for Associated Press and Fox News.

  • Comments
Loading comments...